United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.

United Therapeutics ( NASDAQ: UTHR) has entered into two accelerated share repurchase deal to buy back an aggregate of $1 billion of its common stock. The company will repurchase these shares as part ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per ...

United Therapeutics UTHR is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement. Analysts estimate that United ...

United Therapeutics will repurchase these shares under the $1 billion repurchase program authorized by the company’s board of directors and previously announced on July 30, 2025.

United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report.

UBS analyst Ashwani Verma raised the firm’s price target on United Therapeutics (UTHR) to $415 from $385 and keeps a Buy rating on the shares. UBS ...

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported second-quarter earnings of $309.5 million. On a per-share basis, the Silver Spring ...